Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.

    Article  CAS  Google Scholar 

  2. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.

    Article  CAS  Google Scholar 

  3. Song Y, Straker RJ III, Xu X, et al. Neoadjuvant versus adjuvant immune checkpoint blockade in the treatment of clinical stage III melanoma. Ann Surg Oncol. 2020;27(8):2915–26.

    Article  Google Scholar 

  4. Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–61.

    Article  CAS  Google Scholar 

  5. Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27(2):301–9.

    Article  CAS  Google Scholar 

  6. Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29(8):1861–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Tahsin M. Khan MD, Martha E. Teke MD & Jonathan M. Hernandez MD

  2. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Giorgos C. Karakousis MD & John T. Miura MD

  3. Department of Otorhionolaryngology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Robert M. Brody MD

  4. Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Tara C. Mitchell MD

Authors
  1. Tahsin M. Khan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martha E. Teke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgos C. Karakousis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John T. Miura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert M. Brody MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jonathan M. Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tara C. Mitchell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jonathan M. Hernandez MD or Tara C. Mitchell MD.

Ethics declarations

Disclosure

The authors declare they have no conflicts of interest and nothing to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file 1 (DOCX 175 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khan, T.M., Teke, M.E., Karakousis, G.C. et al. Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab. Ann Surg Oncol 29, 2771–2772 (2022). https://doi.org/10.1245/s10434-021-11199-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-11199-0

Search

Navigation